Corporate Patient
PDMS Log In nSight Log In

ABOUT DRE

When medications fail, waiting puts patients at risk. The average wait for advanced intervention is 16.7 years.1

Delayed intervention for drug-resistant epilepsy (DRE) can reduce the impact of treatment and increase the risk of Sudden Unexpected Death in Epilepsy (SUDEP).

# OF SEIZURES PER MONTH Scroll to walk through 17 years (hypothetical patient)

After two failed medications, the probability of seizure freedom drops below 5%.2

The RNS® System is safe, effective, reversible and non-destructive.

Burden of DRE

Drug-resistant epilepsy (DRE) is a life-threatening condition. Uncontrolled seizures kill 1 in 150 patients per year.3

When seizures are uncontrolled, patients are:

  • 6x

    more likely to have depression4*

  • 4.5x

    more likely to be prevented from driving4*

  • 3x

    more likely to experience limitations in employment4*

  • 2x

    more likely to have limits in education4*

We have a responsibility to try to reduce the seizure burden for every patient we meet with epilepsy. Complacency is the enemy.

Dr. Martha Morrell
Chief Medical Officer at NeuroPace

Patient Selection

Every focal DRE patient should be evaluated for the RNS System.

Get Started

RNS Indication

  • 18+ years of age
  • Refractory to two or more medications
  • Focal Epilepsy with 1-2 seizure foci

Who Can Benefit from the RNS® System:

  • Patients who do not want a destructive brain surgery
  • Patients who are not a candidate for destructive surgery
  • Have not achieved seizure control with VNS or destructive surgery
Get Started

Learn More About The RNS System

Life changing outcomes

Unmatched seizure control that lets your patients take back their lives

Confident Care

Simplified iEEG insights help you confidently manage your patients' epilepsy care

Easily get your patients started with The RNS® System

Whether you're evaluating your first candidate or you want to establish the RNS System as your standard of care, we are here to help.

Contact NeuroPace Find a Center

Rx Only. The RNS® System is an adjunctive therapy for adults with refractory, partial onset seizures with no more than 2 epileptogenic foci. See important prescribing and safety information at www.NeuroPace.com/safety. Refer to the labeling for a description of the RNS System and its components, indications for use, contraindications, warnings, cautions, adverse events and instructions for use.

  1. Campbell et al., Epilepsia, 2024
  2. Chen Z, et al. "Treatment Outcomes in Patients with Newly Diagnosed Epilepsy Treated with Established and New Antiepileptic Drugs." JAMA Neurology. 2018.
  3. Epilepsy Foundation of Northern California
  4. Josephson CB, Patten SB, Bulloch A, et al. The impact of seizures on epilepsy outcomes: a national, community-based survey. Epilepsia. 2017;58(5):764-771.

* Based on data that compared patients who had ≥1 seizure in the past 5 years with those who experienced no seizures in the past 5 years.

© 2026 NeuroPace, Inc. All rights reserved. NeuroPace and RNS are registered trademarks of NeuroPace, Inc., Mountain View, CA

NP 260046 Rev1 / Rev Date 2026-04